cyrilzakka/clinical-trials huggingface dataset:
A Cohort Study of Environmental Endocrine Disrupting Chemicals and Female Reproductive Health

Infertility is a disease that seriously affects the physical and mental health of women of childbearing age. The incidence of infertility has been increasing in recent years. Studies have shown that the occurrence of infertility may be related to environmental endocrine disrupting substances. This project was designed to establish a cohort study on environmental endocrine disrupting substances and in vitro fertilization (IVF) treatment, collect blood, urine, semen, follicular fluid, granulosa cells, chorionic decidua biological specimens, and then follow up on the pregnancy outcomes. The concentration of disrupting substances was detected and then found the associations between environmental endocrine disrupting substances and female reproductive health.


Eligibility Criteria:
Inclusion Criteria:

Clinical diagnosis of infertile patients undergoing IVF treatment

Exclusion Criteria:

Donor egg transplants excluded
Fat Layer Reduction in the Lateral Thighs Using CoolSculpting

Evaluate the performance of a cryolipolysis system using a colder treatment parameter for non-invasive reduction of subcutaneous fat in the lateral thighs.

Evaluation of the Zeltiq CoolSculpting System for non-invasive subcutaneous fat reduction in the lateral thighs.

Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects \> 22 years of age and \< 65 years of age.
* Subject has clearly visible fat on the intended treatment area (lateral thighs), which in the investigator's opinion, may benefit from the treatment.
* Subject has not had weight change exceeding 10 pounds in the preceding month.
* Subject with body mass index (BMI) up to 35. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches.
* Subject agrees to maintain his/her weight (i.e., within 5%) by not making any major changes in their diet or exercise routine during the course of the study.
* Subject has read and signed a written informed consent form.

Exclusion Criteria:

* Subject has had a surgical procedure(s) in the area of intended treatment.
* Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.
* Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 4 months.
* Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.
* Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.
* Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.
* Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
* Subject is taking or has taken diet pills or supplements within the past month.
* Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).
* Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system
* Subject is pregnant or intending to become pregnant during the study period (in the next 4 months).
* Subject is lactating or has been lactating in the past 6 months.
* Subject is unable or unwilling to comply with the study requirements.
* Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.
* Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
Alexander Technique, Routine Physical Therapy, Balance, Posture, Functional Mobility , Chronic, Hemorrhagic, Stroke

MATERIALS AND METHODS Design: The randomized controlled trial. Setting: Nusrat Abdul Rauf Centre for Enablement, Faisalabad. Sample size:40 in each group. Experimental group: Recieve Alexander Technique with Routine Physical Therapy. Control Group: Recieve Routine Physical Therapy.

Control Group: Routine Physical Therapy duration: two days a week for 16 weeks.

Trunk stabilising exercises time duration will be 15 minutes,

Straight static standing.Time duration 15 minutes. Shoulders extend. Threestepsfeet placement.10cm away. Open eye target at 2m away. Arms by side.

Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Raise heel with straight foot \& straight head. 20 minutes. Foot raise with straight foot \& straight head. 20 minutes. Rest.5 minutes.

Experimental Group: Alexander Technique + Routine Physical Therapy duration for two days a week for 16 weeks. Lessons will be 32.

Verbal Instructions in Trunk stabilising exercises. Lift the lumber, Head in Centre, fix hands and feet. The time duration will be 15 minutes,

Verbal instructions in Stance Phase:

Relax-Lighten up-Relax-Pull-up. "Shoulder back", "head up", "tummy in" and "stand up straight".

Hip and feet width apart.

Straight static standing.Time duration 15 minutes. Shoulders extend. Threestepsfeet placement.10cm away. Open eye target at 2m away. Arms by side.

Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Raise heel with straight foot \& straight head. 20 minutes. Foot raise with straight foot \& straight head. 20 minutes. Rest.5 minutes.

Eligibility Criteria:
Inclusion Criteria:

* Chronic Hemorrhagic Hemiplegic Stroke.
* Age40-60Yrs.
* Both genders.
* Intact cognition by MMSE.
* Muscle tone assessment by Ashworth scale.
* Right or left side.
* 6th month onset. Exclusion Criteria: -
* Dizziness.
* Vertigo.
* Cerebellum damage.
* Hearing impairment.
* Vision impairment
Multi-Component Prehabilitation for Major Elective Surgery

The purpose of this pilot study is to assess the feasibility of delivering a multicomponent prehabilitation and measuring patient-centered outcomes in older adults undergoing major surgery.

We will assess the feasibility of delivering a multicomponent prehabilitation, which consists of exercise (supervised by physical therapist), nutritional intervention (nutritional supplement and group education), meditation (group class), and cognitive behavioral intervention over 3-4 weeks before major elective abdominal, gynecological oncologic, urologic surgery, and cardiovascular procedures. We will also measure patient-centered outcomes (Patient-Reported Outcomes Measurement Information System) at 30 and 90 days after surgery. The target enrollment is 30 patients.

Eligibility Criteria:
Inclusion Criteria:

* Patient is scheduled to have a gastrointestinal, gynecological oncologic, urologic, and cardiovascular procedure
* Age 70 years+
* Age 65 years+ AND high risk per surgeon's clinical judgment
* Patient provides an informed e-consent or remote consent

Exclusion Criteria:

* Surgery is scheduled less than 21 days
* Patient is considered an inappropriate candidate per the surgeon's assessment
* Non-English speaking
* Patient has a major cognitive impairment confirmed by telephone Montreal Cognitive Assessment (MoCA) \<18 or Brief Capacity Assessment Questionnaire
* Patients with chronic kidney disease stage 3 or higher will be excluded from receiving protein supplement of the prehabilitation program
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients

To evaluate the efficacy of targeted CAIX-specific probe PET imaging in the diagnosis and staging of kidney cancer, as well as to assess its role in prognosis prediction and treatment evaluation for kidney cancer.

Images will be analyzed by at least two physicians with extensive experience in nuclear medicine and radiological diagnostics. Regions of interest (ROIs) will be delineated for the lesion tissues to measure volume and SUV values. The interpreted PET/CT imaging results will be compared to the corresponding histopathological results of the lesions (obtained through biopsy or surgery) and will be used as the reference standard. We will employ McNemar's test to compare the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of targeted CAIX PET/CT imaging and enhanced CT in primary tumors, metastatic lymph nodes, and distant metastatic lesions.

Eligibility Criteria:
Inclusion Criteria:

1. Voluntary participation with the patient or their legal representative able to sign the informed consent form.
2. Adult patients (age between 18 and 75 years), regardless of gender.
3. Patients with clinically suspected or confirmed primary kidney cancer (supporting evidence includes imaging data and histopathological examination; specific case types include clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma) who agree to undergo histopathological examination (if not already performed prior to imaging).
4. Patients must have undergone enhanced CT, with the enhanced CT examination conducted within 2 weeks prior to enrollment.
5. ECOG performance status score of 0-3.
6. Laboratory parameters must meet the following criteria:

   1. ALT and AST must not exceed 3 times the upper limit of normal; BUN and creatinine must not exceed 1.5 times the upper limit of normal.
   2. Hematological parameters: 2 x 10\^9/L ≤ WBC ≤ 2 x 10\^10/L, PLT ≥ 80 x 10\^9/L, Hb ≥ 80 g/L.
7. Willing and able to comply with follow-up visits, treatment plans, and related laboratory examinations.

Exclusion Criteria:

1. Pregnant or breastfeeding patients (all women of childbearing age must undergo pregnancy testing during the screening phase, such as a urine pregnancy test or blood HCG test, to confirm their pregnancy status).
2. Patients or their legal representatives who are unable or unwilling to sign the informed consent form.
3. Acute systemic diseases and electrolyte imbalances.
4. Patients unable to complete the PET/CT examination (including those unable to lie flat, those with claustrophobia, radiophobia, etc.).
5. Researchers believe that the patient has poor compliance or has other factors making them unsuitable for participation in this study.
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

This 2 arm study will investigate Quality of Life response in anemic participants with solid and lymphoid malignancies, who are receiving concomitant chemotherapy. Participants with solid and lymphoid malignancies will receive epoetin beta at a dose of 150 international units per kilogram (IU/kg) three times weekly. Participants with lymphoid malignancies will receive epoetin beta 30000 IU once weekly.


Eligibility Criteria:
Inclusion Criteria:

* Anemia and prescribed treatment with epoetin beta
* Confirmed diagnosis of a solid or lymphoid hematologic malignancy
* Receiving or scheduled to receive chemotherapy
* Life expectancy of greater than or equal to (\>=6) months

Exclusion Criteria:

* Anemia after bleeding, hemolytic anemia, megaloblastic anemia, anemia in chronic kidney failure, lever and endocrinology diseases
* Contraindications to epoetin beta
* Administration of epoetin beta during chemotherapy (e.g., on the third day after chemotherapy cycle start)
* Bleeding within one month before and/or during study
* Severe infection within one month before and/or during study
* Inability of participant to fill the questionnaires
Character Strengths Intervention Among Psychiatrically Hospitalized Youth

Research has shown that identifying and using one's character strengths in new ways decreases depressive symptoms and increases happiness in adults in the general population. Recently, we found that a similar intervention increases the self-esteem and self-efficacy of children and adolescents being treated in an inpatient psychiatric unit. The purpose of this study is to better understand the effects that discovering one's character strengths and incorporating them into coping skills will have on treatment outcomes in patients admitted to a child and adolescent inpatient psychiatric unit.

The primary aim of this study is to investigate whether a character strengths-based intervention results in significant improvements in measures of depression, anxiety, resiliency, optimism, self-perception, and life-satisfaction of psychiatrically hospitalized youth up to three months following admission. Secondary aims are to: (1) examine participants' strengths profile to identify potential correlates between character strengths, psychiatric diagnoses and intervention effectiveness; and (2) determine whether patients who continue to incorporate their strengths into coping skills at follow-up assessments exhibit greater improvement over-time.

Participants will be 210 adolescents aged 12 to 17 years admitted to the Child and Adolescent Psychiatric Inpatient Program and will be randomized into one of the three groups. All participants will complete the Values in Action Inventory of Strengths for Youth (VIA-Youth) Survey on their second hospital day and subsequently receive the signature strengths intervention (experimental group), coping skills with memory aids comparison exercise (positive control group), or coping skills without memory aids (treatment-as-usual control group). Outcome measures will be completed by all participants at baseline (day 1 on unit), post-treatment (day 4 on unit), and 1- and 3-months following admission. The proposed research represents a change in paradigm, as we aim to specifically examine the therapeutic benefit of the positive psychology element of our intervention conducted in the pilot study among youth with severe mental illness.

Eligibility Criteria:
Inclusion Criteria:

* Patient on Child and Adolescent Psychiatric Unit

Exclusion Criteria:

* Cognitive disability or severe psychosis preventing understanding of survey measures
* Prior use of VIA-Youth Survey
* Absence of legal guardian to consent
Impact of High Dietary Fiber on Microbiome and Vaccine Responses

To learn if diet can enhance the microbes (such as bacteria and viruses) found in your gut and improve the body's immune response to the influenza (flu) vaccine.

Primary Objectives:

--To determine the feasibility of two dietary intervention strategies focused on fiber-rich and prebiotic foods prior to seasonal influenza vaccination. Feasibility is defined as ≥ 80% of subjects being compliant with the intervention.

Secondary Objectives:

* To evaluate the effects of each dietary intervention on the composition, diversity and function of the gut microbiome.
* To assess the effects of each dietary intervention on response to influenza vaccination as measured by vaccine-specific immune response.
* To assess the effects of each dietary intervention on systemic immunity.

Exploratory Objectives:

* To interrogate the overlap between the identified gut microbial and dietary patterns associated with vaccine response and those associated with excellent or poor responses to cancer immunotherapy (from our own published work and internal cohorts).
* To identify components and determinants of the gut microbiome that could be modulated to enhance vaccine response.
* To determine how modulation of the gut microbiome can be achieved through fiber and prebiotic-focused dietary changes.

Eligibility Criteria:
Inclusion Criteria:

1. MD Anderson employees with existing MRNs
2. Body Mass Index (BMI) 18.5-40 kg/m2
3. Age 18 or older
4. Intends to receive the seasonal influenza vaccine at MD Anderson through Employee Health (starting Fall of 2022)
5. Willing to adhere to the provided dietary interventions
6. Willing to provide blood and stool specimens, complete diet questionnaires and logs, and pick up food on-site within the study schedule
7. English-speaking
8. Has easy access to a scale at home, work, or in their community

Exclusion Criteria:

1. Contraindication to the recommended annual influenza vaccine
2. Medical contraindications to the intervention diet
3. Major dietary restrictions (including vegetarian or vegan diets) or food allergies
4. Unable or unwilling to undergo study procedures
5. Has diabetes mellitus requiring medical treatment
6. Has inflammatory bowel disease
7. Has a history of bariatric surgery
8. Has a history of major gastrointestinal surgery (not including appendectomy or cholecystectomy)
9. Antibiotic use within 30 days of study initiation or planned antibiotic treatment during study course
10. Habitual consumption of a high fiber diet
11. Use of a supplement containing fiber/prebiotics/probiotics within 30 days of study initiation
12. Women who are pregnant, planning to become pregnant, or who are lactating may not be included in this study
A Trial of Rehabilitation in Obesity Hypoventilation Syndrome (OHS)

Obesity is an escalating problem in the UK and a proportion of these patients have a condition known as Obesity Hypoventilation Syndrome (OHS). This syndrome is associated with symptoms of breathlessness, reduction in exercise capacity, fatigue and headaches. Previous research has shown that patients with this condition tend to use healthcare services more frequently and are often at risk of other diseases such as diabetes mellitus and high blood pressure. Currently, the mainstay of treatment is noninvasive ventilation (NIV), this is a mask ventilator that patients use overnight to improve oxygen levels and remove carbon dioxide (the waste gas of breathing), however this does not fully treat the underlying problem. The research group has shown that NIV helps improve activity and contributes to weight loss in this group of patients. The aim of this research will be to investigate the effect of an exercise and nutrition programme in addition to NIV on weight loss and activity levels compared to NIV alone.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of OHS
* Age \>18
* BMI \> 30 kg/m2
* Chronic hypercapnia , daytime PaCO2 \>6kPa
* FEV1/FVC ≥70%
* Evidence of sleep disordered breathing on overnight studies
* Tolerated NIV \> 4hrs on 1st night during initiation of NIV

Exclusion Criteria:

* Hypercapnic respiratory failure secondary to an identifiable cause other than OHS.
* Age \<18
* Respiratory acidosis (pH \<7.35)
* Wheelchair/bedbound patients
* Cognitive impairment which would prevent the subject from complying with trial protocol
* Unstable coronary artery syndrome
* Patients postintubation or decannulation following treatment requiring acute hypercapnic respiratory failure
* Patients undergoing renal replacement therapy
* Critical peripheral vascular disease
* Disabling locomotor disability preventing participation in exercises involved in the rehabilitation programme
* Pregnancy
* Bariatric surgery planned within 3 months
Safety Study of Nicotinamide to Treat Alzheimer's Disease

The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.

The goal of this proposal is to show that, nicotinamide (NA), a B3 vitamin, is safe and effective for the treatment of patients with mild to moderate Alzheimer's disease (AD). NA is known to block the ability of certain proteins to regulate other proteins by removing their acetyl groups. Recent evidence has demonstrated that inhibitors such as NA prevent nerve cell degeneration in models of Huntington's disease (HD), Parkinson's disease and Lou Gehrig's disease (or ALS). Despite these beneficial effects in many different animal models, there have been no studies to date using these inhibitors in AD. In some of our recent studies we found that the potent inhibitor, NA, significantly improves learning and memory in transgenic mice that develop AD. NA treatment also resulted in striking changes in tau, a protein that abnormally accumulates in AD. NA has been extensively used in clinical studies over the last 40 years and is generally safe and well-tolerated. As NA is a safe and readily available vitamin supplement, our recent results provide a strong argument for a study of NA in patients with AD. We therefore propose to treat 50 patients with mild to moderate AD with either NA (1500 milligrams twice a day) or an identical but inactive drug (placebo) for 24 weeks. At 6 week intervals we will assess functions such as learning and memory, and ability to carry out daily activities as well as caregiver reports using standardized tests. We will also perform spinal taps at the beginning and end of the study to measure the level of abnormal tau protein in the cerebrospinal fluid. Blood tests will periodically be done to assess liver function and complete blood counts. The results of this study may provide the basis for a more extensive study of NA for the treatment of mild to moderate AD.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of probable AD according to DSM-IV criteria
* Mild to moderate dementia based on Mini-Mental State Examination \[MMSE\] score between 13-25
* Minimum age 50 years
* Brain imaging (computed tomographic scan or magnetic resonance image) within 12 months consistent with a diagnosis of probable AD
* Hachinski Ischemic Score of \<4.
* Stable doses of concomitant medications, including cholinesterase inhibitors (ChEIs) and/or memantine.

Exclusion Criteria:

* Dementia due to another cause
* Other neurological or psychiatric diseases
* Pseudodementia
* Unstable medical condition
* Initial treatment within 30 days of screening with a ChEI, memantine or any investigational drug
* History of alcoholism, drug abuse, liver disease, peptic ulcer disease
* Pregnancy, or the potential to become pregnant.